Exxel Pharma, Inc. | Finanzwire

Basculer en Français

8295	Companies
114833	Keywords
55274	Articles
62430	Press releases

Home
Companies
Exxel Pharma, Inc.

BRIEF

published on 05/01/2024 at 16:05, 6 months 19 days ago

Exxel Pharma to Showcase in Virtual Investor Lunch Break

Exxel Pharma EX937 Virtual Investor Event Chronic Cough Treatment Pharmaceutical Development
PRESS RELEASE

published on 05/01/2024 at 16:00, 6 months 19 days ago

Exxel Pharma to Participate in the Virtual Investor Lunch Break: The Exxel Opportunity
Soren Mogelsvang, PhD, CEO of Exxel Pharma, to present at Virtual Investor Lunch Break event discussing Exxel opportunity on May 8th. EX937 development updates

Exxel Pharma EX937 Virtual Investor Lunch Break Chronic Cough Treatment Soren Mogelsvang
PRESS RELEASE

published on 01/25/2024 at 16:00, 9 months 26 days ago

Exxel Pharma Provides Business Overview and Upcoming Milestones
Exxel Pharma provided a business overview of its lead program, EX937, an innovative small molecule for treating refractory chronic cough, a condition currently with no FDA-approved therapies. The program demonstrates a differentiated approach with preclinical efficacy and safety, aiming for potential value-driving milestones in 2024 and addressing a large underserved market. The company expects EX937 to have a significant impact on improving the quality of life for adults suffering from chronic cough, with potential broad clinical applications and commercial opportunities.

Exxel Pharma EX937 Refractory Chronic Cough FAA Enzyme Neuronal Hypersensitivity
PRESS RELEASE

published on 10/11/2023 at 16:00, 1 year 1 month ago

Exxel Pharma to Participate in the Virtual Investor Ask the CEO Conference

Accesswire

Published on 11/21/2024 at 10:03, 39 minutes ago

Pixotope Launches Revolutionary AI-Powered Graphics Integration Tool for Broadcast Industry
Published on 11/21/2024 at 10:00, 42 minutes ago

BluSky Carbon JV Entity BluMountain Enters into JV Partnership in Southeastern USA
Published on 11/21/2024 at 09:00, 1 hour 42 minutes ago

ProScore Announces Domestic Content Solution for Inflation Reduction Act Requirements
Published on 11/21/2024 at 00:35, 10 hours 7 minutes ago

Vision Marine Technologies Establishes a Strategic Hub for Electric Boat Sales, Rentals, and Distribution, Marking a Milestone at Dania Pointe’s Grand Opening of Aileron Residences
Published on 11/21/2024 at 00:25, 10 hours 17 minutes ago

Biomind Labs Welcomes U.S. Policy Shift as a Historic Milestone for Psychedelic Therapies

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 10:30, 12 minutes ago

MS Industrie AG publishes unaudited key figures for the first 3 quarters 2024
Published on 11/21/2024 at 10:04, 37 minutes ago

Supervisory Board appoints Carsten Schmitt as new CFO
Published on 11/21/2024 at 10:02, 40 minutes ago

Supervisory Board appoints Carsten Schmitt as new CFO
Published on 11/21/2024 at 10:00, 42 minutes ago

Nabaltec AG continues solid earnings performance in third quarter of 2024
Published on 11/21/2024 at 10:00, 42 minutes ago

Deutsche Beteiligungs AG: Successful final closing of DBAG ECF IV

Les Echos

Published on 11/21/2024 at 06:58, 3 hours 44 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 15 hours 22 minutes ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 16 hours 57 minutes ago

MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 16 hours 57 minutes ago

Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 2 hours ago

Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo

View all LES ECHOS COMFI WIRE